Phase II study of paclitaxel (BMS-181339) in patients with ovarian cancer by 3 hour intravenous infusion

Japanese Journal of Cancer and Chemotherapy

Volumn 23, Issue 3, 1996, Pages 317-325

  Noda, K ^a   Ikeda, M ^a   Kudo, R ^a   Nishiya, I ^a   Yajima, A ^a   Tanaka, K ^a   Kodama, S ^a   Takahashi, T ^a   Tokunaga, A ^a   Satoh, I ^a   Nozawa, S ^a   Taketani, Y ^a   Terashima, Y ^a   Isonishi, S ^a   Takeda, Y ^a   Nishijima, M ^a   Kuroshima, Y ^a   Fujii, S ^a   Izumi, R I ^a  

^a SAPPORO MEDICAL UNIVERSITY   (Japan)

Author keywords

3 hr infusion; Ovarian cancer; Paclitaxel; Phase II study

Indexed keywords

PACLITAXEL; PLATINUM;

ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MAJOR CLINICAL STUDY; NEUTROPENIA; OVARY CANCER; PHASE 2 CLINICAL TRIAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; JAPAN; LEUKOPENIA; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL; PERIPHERAL NERVOUS SYSTEM DISEASES; REMISSION INDUCTION; THROMBOCYTOPENIA;

EID: 0030058053     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)